Sporadic Inclusion Body Myositis
📧 Sign up to get email alerts when something new happens for Sporadic Inclusion Body Myositis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Sporadic Inclusion Body Myositis Natural History Study
A natural history study of sporadic inclusion body myositis and inclusion body myositis at the University of California, Irvine is currently…
-
CLINICAL_TRIALS research · 2026-01-16Clinical Trial Update: Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis [EARLY_Phase 1]
An EARLY_PHASE1 clinical trial is evaluating the efficacy and safety of a combination of pozelimab and cemdisiran in Sporadic Inclusion Body…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis [Phase 1]
Phase 1 trial update reporting safety and tolerability data for phenylbutyrate in Inclusion Body Myositis, with the study status shown as co…
-
CLINICAL_TRIALS trial_result · 2020-12-17Clinical Trial Update: Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis [Phase 2]
Phase 2 trial evaluating BYM338 for efficacy, safety, and tolerability in Sporadic Inclusion Body Myositis completed.
-
CLINICAL_TRIALS trial_result · 2018-04-10Clinical Trial Update: Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis [Phase 2, Phase 3]
Clinical trial update on long-term safety, efficacy, and tolerability of BYM338 in sporadic inclusion body myositis completed with results p…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-03-13Clinical Trial Update: An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203 [Phase 3]
This extension study evaluates the efficacy, safety, and tolerability of BYM338 (bimagrumab) in patients with sporadic inclusion body myosit…
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: Immune Abnormalities in Sporadic Inclusion Body Myositis
This completed clinical trial update summarizes immune abnormalities observed in sporadic inclusion body myositis.
-
CLINICAL_TRIALS trial_result · 2017-05-12Clinical Trial Update: Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients [Phase 2, Phase 3]
Phase 2/3 trial update evaluating the 52-week efficacy and safety of bimagrumab (BYM338) in Sporadic Inclusion Body Myositis, assessing phys…
-
CLINICAL_TRIALS research · 2016-04-18Clinical Trial Update: Pharmacoepidemiologic General Research Extension: PGRx-sIBM Study
This entry provides an update on the Pharmacoepidemiologic General Research Extension: PGRx-sIBM Study (NCT02735447) sponsored by La-ser Eur…
-
CLINICAL_TRIALS trial_result · 2015-10-20Clinical Trial Update: Blood-flow Restricted Exercise in Inclusion Body Myositis [NA]
A clinical trial evaluating blood-flow restricted exercise in Sporadic Inclusion Body Myositis has completed.